239 related articles for article (PubMed ID: 9201407)
1. Retroviral insertional mutagenesis of a herpesvirus: a Marek's disease virus mutant attenuated for oncogenicity but not for immunosuppression or in vivo replication.
Witter RL; Li D; Jones D; Lee LF; Kung HJ
Avian Dis; 1997; 41(2):407-21. PubMed ID: 9201407
[TBL] [Abstract][Full Text] [Related]
2. Insertion of reticuloendotheliosis virus long terminal repeat into a bacterial artificial chromosome clone of a very virulent Marek's disease virus alters its pathogenicity.
Mays JK; Silva RF; Kim T; Fadly A
Avian Pathol; 2012; 41(3):259-65. PubMed ID: 22702453
[TBL] [Abstract][Full Text] [Related]
3. Insertion of reticuloendotheliosis virus long terminal repeat into the genome of CVI988 strain of Marek's disease virus results in enhanced growth and protection.
Lupiani B; Lee LF; Kreager KS; Witter RL; Reddy SM
Avian Dis; 2013 Jun; 57(2 Suppl):427-31. PubMed ID: 23901756
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of Marek's disease virus (MDV) glycoprotein-, lytic antigen pp38- and transformation antigen Meq-encoding genes: association of meq mutations with MDVs of high virulence.
Shamblin CE; Greene N; Arumugaswami V; Dienglewicz RL; Parcells MS
Vet Microbiol; 2004 Sep; 102(3-4):147-67. PubMed ID: 15327791
[TBL] [Abstract][Full Text] [Related]
5. Cell culture attenuation eliminates rMd5ΔMeq-induced bursal and thymic atrophy and renders the mutant virus as an effective and safe vaccine against Marek's disease.
Lee LF; Heidari M; Zhang H; Lupiani B; Reddy SM; Fadly A
Vaccine; 2012 Jul; 30(34):5151-8. PubMed ID: 22687760
[TBL] [Abstract][Full Text] [Related]
6. Increased virulence of Marek's disease virus field isolates.
Witter RL
Avian Dis; 1997; 41(1):149-63. PubMed ID: 9087332
[TBL] [Abstract][Full Text] [Related]
7. Increased virulence of Marek's disease virus type 1 vaccine strain CV1988 after adaptation to qt35 cells.
Majerciak V; Valkova A; Szabová D; Geerligs H; Zelník V
Acta Virol; 2001 Apr; 45(2):101-8. PubMed ID: 11719980
[TBL] [Abstract][Full Text] [Related]
8. Host responses in the bursa of Fabricius of chickens infected with virulent Marek's disease virus.
Abdul-Careem MF; Hunter BD; Lee LF; Fairbrother JH; Haghighi HR; Read L; Parvizi P; Heidari M; Sharif S
Virology; 2008 Sep; 379(2):256-65. PubMed ID: 18675437
[TBL] [Abstract][Full Text] [Related]
9. Multiple infection of chickens and turkeys with avian oncogenic viruses: prevalence and molecular analysis.
Davidson I; Borenstein R
Acta Virol; 1999; 43(2-3):136-42. PubMed ID: 10696434
[TBL] [Abstract][Full Text] [Related]
10. Relationship between the immunosuppressive potential and the pathotype of Marek's disease virus isolates.
Calnek BW; Harris RW; Buscaglia C; Schat KA; Lucio B
Avian Dis; 1998; 42(1):124-32. PubMed ID: 9533089
[TBL] [Abstract][Full Text] [Related]
11. Biocharacteristics shared by highly protective vaccines against Marek's disease.
Gimeno IM; Witter RL; Hunt HD; Reddy SM; Reed WM
Avian Pathol; 2004 Feb; 33(1):59-68. PubMed ID: 14681069
[TBL] [Abstract][Full Text] [Related]
12. Properties of a meq-deleted rmd5 Marek's disease vaccine: protection against virulent MDV challenge and induction of lymphoid organ atrophy are simultaneously attenuated by serial passage in vitro.
Lee LF; Kreager K; Heidari M; Zhang H; Lupiani B; Reddy SM; Fadly A
Avian Dis; 2013 Jun; 57(2 Suppl):491-7. PubMed ID: 23901766
[TBL] [Abstract][Full Text] [Related]
13. Artificially inserting a reticuloendotheliosis virus long terminal repeat into a bacterial artificial chromosome clone of Marek's disease virus (MDV) alters expression of nearby MDV genes.
Kim T; Mays J; Fadly A; Silva RF
Virus Genes; 2011 Jun; 42(3):369-76. PubMed ID: 21340512
[TBL] [Abstract][Full Text] [Related]
14. In vivo events of retroviral long terminal repeat integration into Marek's disease virus in commercial poultry: detection of chimeric molecules as a marker.
Davidson I; Borenshtain R
Avian Dis; 2001; 45(1):102-21. PubMed ID: 11332471
[TBL] [Abstract][Full Text] [Related]
15. Attenuated revertant serotype 1 Marek's disease viruses: safety and protective efficacy.
Witter RL
Avian Dis; 1991; 35(4):877-91. PubMed ID: 1664721
[TBL] [Abstract][Full Text] [Related]
16. Derivation, safety and efficacy of a Marek's disease vaccine developed from an Australian isolate of very virulent Marek's disease virus.
Karpathy RC; Firth GA; Tannock GA
Aust Vet J; 2002; 80(1-2):61-6. PubMed ID: 12180882
[TBL] [Abstract][Full Text] [Related]
17. Association between rate of viral genome replication and virulence of Marek's disease herpesvirus strains.
Yunis R; Jarosinski KW; Schat KA
Virology; 2004 Oct; 328(1):142-50. PubMed ID: 15380365
[TBL] [Abstract][Full Text] [Related]
18. Serotype 1 viruses modified by backpassage or insertional mutagenesis: approaching the threshold of vaccine efficacy in Marek's disease.
Witter RL; Kreager KS
Avian Dis; 2004 Dec; 48(4):768-82. PubMed ID: 15666858
[TBL] [Abstract][Full Text] [Related]
19. Influence of vaccination with CVI988/Rispens on load and replication of a very virulent Marek's disease virus strain in feathers of chickens.
Haq K; Fear T; Ibraheem A; Abdul-Careem MF; Sharif S
Avian Pathol; 2012; 41(1):69-75. PubMed ID: 22845323
[TBL] [Abstract][Full Text] [Related]
20. Rescue of a pathogenic Marek's disease virus with overlapping cosmid DNAs: use of a pp38 mutant to validate the technology for the study of gene function.
Reddy SM; Lupiani B; Gimeno IM; Silva RF; Lee LF; Witter RL
Proc Natl Acad Sci U S A; 2002 May; 99(10):7054-9. PubMed ID: 11997455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
